Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry, with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell–based HCV vaccine development through E2 optimization and nanoparticle display. We redesigned variable… [Read more]
News release by Scripps Research on the latest research paper on HCV vaccine co-sponsored by NIH and Ufovax
The new approach to vaccine design may also prove useful in developing a potential vaccine against the SARS-CoV-2 virus, which causes COVID-19. LA JOLLA, CA—A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a study… [Read more]
